Lawsuits Against Several Companies for Patent Infringement
NEW YORK, Jan. 10 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX), Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co. KgaA,
and Merz Pharmaceuticals GmbH announced that they have filed lawsuits in the
U.S. District Court for the District of Delaware against several companies for
infringement of U.S. Patent No. 5,061,703 (the '703 patent), which relates to
Forest's Namenda(R) product. The defendants named in the lawsuits include
Barr Laboratories, Inc., Cobalt Laboratories, Inc., Lupin Ltd., Orchid
Chemicals & Pharmaceuticals Ltd., Teva Pharmaceuticals USA, Inc., Upsher-Smith
Laboratories Inc., Wockhardt Ltd., and related companies and subsidiaries
thereof. The '703 patent expires in April 2010. Forest has applied for
patent term extension which, if granted, would extend the '703 patent until
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
As previously reported, Forest had received notification from several
companies that they had filed Abbreviated New Drug Applications with Paragraph
IV certifications to obtain approval to market generic versions of Namenda.
Except for the historical information contained herein, this release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform act of 1995. These statements involve a number
of risks and uncertainties, including the difficulty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, the timely development and launch
of new products, and the risk factors listed from time to time in each of
Forest Laboratories' Annual Reports on Form 10-K, Quarterly Reports on Form
10-Q, and any subsequent SEC filings.
SOURCE Forest Laboratories, Inc.
Charles E. Triano, Vice President, Investor Relations of Forest Laboratories,
Inc., +1-212-224-6714, email@example.com
-0- Jan/10/2008 22:05 GMT
Press spacebar to pause and continue. Press esc to stop.